About Dr. Zhao Weili
Dr. Zhao Weili (赵维莎) is one of China's most distinguished hematologists and a globally recognized authority on lymphoma and hematologic malignancies. She serves as Director of the Department of Hematology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and holds the title of Chief Physician and Professor.
Dr. Zhao is a member of the Chinese Academy of Sciences (中国科学院院士) — China's highest academic honor — making her one of the most decorated hematologists in the country and among a very small number of women to hold this distinction in the medical sciences. She is also a Fellow of the American Society of Hematology (ASH) and has served on the editorial boards of leading international journals including Blood, Leukemia, and the Journal of Clinical Oncology.
Her research has fundamentally advanced the understanding of lymphoma biology and treatment in China, and her clinical protocols are now adopted as national standards. Over a career spanning more than three decades, Dr. Zhao has built Ruijin Hospital's Hematology Department into one of the most respected blood cancer centers in Asia. International patients with lymphoma, leukemia, or other hematologic malignancies seeking care in China consistently identify Dr. Zhao as one of the top specialists to consult — both for primary treatment and for second opinions on complex or refractory cases.
Professional Positions and Affiliations
- Director, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Member, Chinese Academy of Sciences (中国科学院院士)
- Past President, Chinese Society of Hematology
- Chair, Lymphoma Committee, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member: Blood, Leukemia, Journal of Clinical Oncology, Annals of Oncology
- Fellow, American Society of Hematology (ASH)
- Member, European Hematology Association (EHA)
- Principal Investigator, multiple ongoing clinical trials registered with ClinicalTrials.gov
Specialties and Clinical Expertise
Dr. Zhao's clinical practice encompasses the full spectrum of hematologic malignancies, with particular depth in lymphoma and leukemia. Her approach integrates the latest molecular diagnostics with individualized treatment planning, ensuring each patient receives a precision medicine strategy tailored to their specific disease biology.
- Lymphoma — diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, NK/T-cell lymphoma, Hodgkin lymphoma, and primary mediastinal B-cell lymphoma; including relapsed and refractory disease management
- Leukemia — acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML); including complex cytogenetic and molecular subtypes
- Multiple Myeloma — novel agent combinations (proteasome inhibitors, IMiDs, anti-CD38 monoclonal antibodies), autologous stem cell transplantation, and maintenance therapy protocols
- Hematopoietic Stem Cell Transplantation (HSCT) — autologous and allogeneic transplantation for hematologic malignancies; graft-versus-host disease (GVHD) management
- CAR-T Cell Therapy — clinical trial leadership and patient selection for CD19, CD22, and BCMA-targeted CAR-T therapies; management of cytokine release syndrome (CRS) and neurotoxicity
- Precision Medicine in Hematology — next-generation sequencing (NGS), genomic profiling, molecular targeted therapy, and biomarker-driven treatment selection
- Myelodysplastic Syndromes (MDS) — IPSS-R risk stratification, hypomethylating agent therapy, and transplantation evaluation
- Bispecific Antibody Therapy — emerging immunotherapy approaches for relapsed/refractory lymphoma and myeloma
Academic and Research Contributions
Dr. Zhao Weili has published over 300 peer-reviewed papers in top international journals, with a particular focus on the molecular pathogenesis of lymphoma and the development of novel targeted therapies. Her landmark research on the genetic landscape of diffuse large B-cell lymphoma (DLBCL) in Chinese patients — revealing distinct molecular subtypes with different prognostic and therapeutic implications compared to Western populations — has been cited extensively in international guidelines and has directly influenced treatment protocols for Asian patients worldwide.
She has led or co-led numerous national and international multicenter clinical trials, bringing cutting-edge therapies — including BTK inhibitors (ibrutinib, zanubrutinib, orelabrutinib), BCL-2 inhibitors (venetoclax), PD-1 checkpoint inhibitors, and CAR-T cell therapies — to Chinese patients years ahead of standard regulatory approval. Her work has been instrumental in establishing China as a global leader in hematology clinical research.
Dr. Zhao is a past President of the Chinese Society of Hematology and currently chairs the Lymphoma Committee of the Chinese Society of Clinical Oncology (CSCO), where she leads the development of national lymphoma treatment guidelines. She is a regular invited speaker and session chair at the world's leading hematology conferences, including ASH (American Society of Hematology), EHA (European Hematology Association), and ICML (International Conference on Malignant Lymphoma).
Her H-index and citation metrics place her among the most impactful hematology researchers in Asia, and she has received numerous national science and technology awards for her contributions to hematology research and clinical practice.
Approach to Patient Care
Despite her extraordinary academic profile, Dr. Zhao is known among her patients and colleagues for her meticulous, patient-centered approach to clinical care. She personally reviews complex cases, leads multidisciplinary tumor board discussions, and takes time to explain treatment options clearly to patients and their families. For international patients — who may be navigating an unfamiliar healthcare system while managing a serious diagnosis — her thoroughness and willingness to engage with overseas medical records and second opinion requests is particularly valued.
Dr. Zhao's clinic at Ruijin Hospital sees patients from across China and increasingly from Southeast Asia, the Middle East, and beyond, reflecting her global reputation as a go-to expert for complex lymphoma and leukemia cases.
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital is one of China's most prestigious academic medical centers, consistently ranked among the top five hospitals in the country by the National Health Commission. Founded in 1907, the hospital has over a century of clinical excellence and is home to multiple National Key Clinical Specialties.
The Department of Hematology at Ruijin is a National Key Clinical Specialty and one of the highest-volume hematology centers in China, managing over 5,000 new hematologic malignancy cases annually. The department operates:
- A dedicated Bone Marrow Transplantation Unit with both autologous and allogeneic transplant capability
- A CAR-T Cell Therapy Program — one of the most active in China
- A state-of-the-art Hematology Laboratory with comprehensive molecular diagnostics, cytogenetics, flow cytometry, and NGS capabilities
- A Clinical Trials Unit running multiple Phase I-III studies in lymphoma, leukemia, and myeloma
- A dedicated Lymphoma Multidisciplinary Team (MDT) meeting weekly to review complex cases
The department's combination of clinical volume, research infrastructure, and access to novel therapies makes it one of the most compelling destinations in Asia for patients with hematologic malignancies.
Why International Patients Choose Dr. Zhao Weili
- Chinese Academy of Sciences member — China's highest academic distinction, held by fewer than 1,000 scientists nationwide
- Global lymphoma authority — editorial board member of Blood, Journal of Clinical Oncology, and Annals of Oncology
- Access to cutting-edge clinical trials — CAR-T, bispecific antibodies, BTK inhibitors, BCL-2 inhibitors, and novel combinations often unavailable elsewhere
- National standard-setter — her protocols are adopted as Chinese national guidelines for lymphoma and leukemia treatment
- High-volume center — Ruijin Hematology manages more cases annually than most Western centers, translating to deep institutional expertise
- Second opinion expertise — frequently consulted by international patients seeking validation of overseas diagnoses and treatment plans
- Asian patient population expertise — her research specifically addresses the distinct molecular biology of lymphoma in Asian patients, offering insights not available from Western oncologists
Practical Information for International Patients
- Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
- Appointment Lead Time: 2–4 weeks for new patients; urgent cases may be expedited through CMCS
- Consultation Format: In-person consultation; remote pre-consultation record review available through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Medical Records: CMCS provides full translation of overseas medical records into Chinese prior to consultation
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking consultation or treatment with Dr. Zhao Weili at Ruijin Hospital. Our services include:
- Priority appointment booking and scheduling coordination
- Medical record translation (English ↔ Chinese) prior to consultation
- Remote pre-consultation review — Dr. Zhao's team can review your records before you travel
- On-site interpretation during consultations, procedures, and tumor board discussions
- Accommodation coordination near Ruijin Hospital
- Insurance liaison and billing support
- Post-treatment follow-up coordination with your home country oncologist
- Clinical trial eligibility assessment and enrollment support
For patients with lymphoma or leukemia seeking a second opinion or considering treatment in Shanghai, CMCS can facilitate a remote pre-consultation review of your medical records before you travel, ensuring your appointment with Dr. Zhao is as productive and efficient as possible.
📧 Contact us: contract@medicalsh.com
💬 WeChat: gezhanglao
🌐 medicalsh.com
0 commenti